All In Biotech

Drug Trial Radar · NCT00000665

Studies of the Ocular Complications of AIDS (SOCA) CMV Retinitis Trial: Foscarnet-Ganciclovir Component

Last checked: Nov 19, 2026Latest source record: Mar 14, 2011 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

240

Actual

Start

Not stated

Primary completion

Apr 1992

Sponsor

Sponsor type
NIH
Collaborators
Johns Hopkins University
First posted
Aug 31, 2001

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Primary purpose
Treatment
Who can join
All sexes, from 13 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the relative effectiveness and safety of foscarnet versus ganciclovir for the treatment of cytomegalovirus (CMV) retinitis in people with AIDS; to evaluate the relative effect on survival of the use of these two anti-CMV agents in the treatment of CMV retinitis; to compare the relative benefits of immediate treatment with foscarnet or ganciclovir versus deferral of treatment for CMV retinitis limited to less than 25 percent of zones 2 and 3. CMV retinitis is a common opportunistic infection in patients with AIDS. Ganciclovir is currently the only drug approved for treatment of CMV retinitis in immunocompromised patients. Ganciclovir suppresses CMV infections, and relapse occurs in virtually all AIDS patients when ganciclovir is discontinued. Because of their similar hematologic (blood) toxicities, the simultaneous use of ganciclovir and zidovudine (AZT) is not recommended. More recently the drug foscarnet has become available for investigational use. Studies so far indicate that remission of CMV retinitis occurs in 36 to 77 percent of patients, and that relapse occurs in virtually all patients when the drug is discontinued. The relative effectiveness of foscarnet compared with ganciclovir for the immediate control of CMV infections is unknown. Further, the long-term effects of foscarnet or ganciclovir on CMV retinitis, survival, and morbidity are unknown. There is also no definitive information on the relative effectiveness and safety of deferred versus immediate treatment for CMV retinitis confined to zones 2 and 3.

Conditions

  • Cytomegalovirus Retinitis
  • HIV Infections

Interventions

  • Foscarnet sodiumDrug

  • GanciclovirDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

No primary outcomes listed.

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • UCSD - Shiley Eye Ctr / SOCA

    La Jolla, California

  • UCLA - Jules Stein Eye Institute / SOCA

    Los Angeles, California

  • UCSF - San Francisco Gen Hosp

    San Francisco, California

  • Northwestern Univ / SOCA

    Chicago, Illinois

  • Charity Hosp / Tulane Univ Med School

    New Orleans, Louisiana

  • Johns Hopkins Hosp / SOCA

    Baltimore, Maryland

  • New York Univ Med Ctr / SOCA

    New York, New York

  • New York Hosp - Cornell Med Ctr / Sloan - Kettering / SOCA

    New York, New York

  • Mount Sinai Med Ctr / SOCA

    New York, New York

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.